Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Celsius Therapeutics
Biotech
AbbVie turns up the M&A heat with $250M Celsius buy
AbbVie is embracing summer’s heat, firing up the M&A grill with a $250 million acquisition of inflammatory disease-focused Celsius Therapeutics.
Gabrielle Masson
Jun 27, 2024 11:00am
Former Takeda exec takes reins at Tessa—Chutes & Ladders
Aug 26, 2022 9:30am
Celsius turns up the heat with lead drug selection, $83M funding
Mar 24, 2022 8:00am
What does a virtual J.P. Morgan mean for the meeting's future?
Jan 12, 2021 11:00am
This year's Fierce 15 winners on IPO trends and the decade ahead
Oct 29, 2019 11:27am
